ERBB2 and endometrial carcinoma: Trastuzumab as a single agent did not demonstrate activity against advanced or recurrent endometrial carcinomas with HER2 overexpression or HER2 amplification in a phase II trial, with an ORR of 0%, PFS of 1.84 months and OS of 7.85 months [134].